Trial Profile
Evaluating Safety and Effectiveness of Alemtuzumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Previously Treated with Natalizumab: A Real World Experience.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2016 New trial record